Eliem Therapeutics Inc

NASDAQ ELYM

Download Data

Eliem Therapeutics Inc Net Operating Profit After Tax (NOPAT) 1 year YoY Change (%) for the year ending December 31, 2023: 8.01%

Eliem Therapeutics Inc Net Operating Profit After Tax (NOPAT) 1 year YoY Change (%) is 8.01% for the year ending December 31, 2023, a 517.74% change year over year. Net Operating Profit After Taxes (NOPAT) is a financial metric that represents a company's operating profit after deducting taxes. It is calculated by multiplying the earnings before interest and taxes (EBIT) by (1 - tax rate). NOPAT provides insights into the company's profitability from its core operations while accounting for the impact of taxes. It is useful for assessing the company's operating performance and comparing profitability across different tax environments. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Eliem Therapeutics Inc Net Operating Profit After Tax (NOPAT) for the year ending December 31, 2022 was -43,756,162.21, a 1.30% change year over year.
  • Eliem Therapeutics Inc Net Operating Profit After Tax (NOPAT) for the year ending December 31, 2021 was -44,331,141.03, a -2,677.51% change year over year.
  • Eliem Therapeutics Inc Net Operating Profit After Tax (NOPAT) for the year ending December 31, 2020 was -1,596,074.12, a -42.52% change year over year.
  • Eliem Therapeutics Inc Net Operating Profit After Tax (NOPAT) for the year ending December 31, 2019 was -1,119,903.31.
NASDAQ: ELYM

Eliem Therapeutics Inc

CEO Mr. Robert W. Azelby M.B.A.
IPO Date Aug. 10, 2021
Location United States
Headquarters 23515 NE Novelty Hill Road, Redmond, WA, United States, 98053
Employees 9
Sector Healthcare
Industry Biotechnology
Description

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Similar companies

MNOV

MediciNova Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

CYT

Cyteir Therapeutics Inc

NA

NA

IPSC

Century Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email